Nasdaq
$43.84▲ 2.18%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.24BShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 1d agoRegular26.10.24 02:418-KKey event#●●●#●●●#●●●
IONIS PHARMACEUTICALS INCBullish
Ionis Pharmaceuticals' partner, Roche, announced that the Phase 3 IMAgINATION study of sefaxersen in patients with IgA nephropathy demonstrated a statistically significant 43.1% reduction in proteinuria at 37 weeks compared to placebo. Following these positive results, Roche plans to share the data with health authorities to expedite the regulatory approval process for this treatment.…more
$43.84+2.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:158-KKey event
IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals' partner, GSK, has received U.S. FDA approval for HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B. The approval is supported by Phase 3 B-Well trial data, and under the existing licensing agreement, Ionis is eligible to receive tiered royalties of 10-12% on net sales, along with additional regulatory and sales milestone payments.…more
$43.84+2.18%vs prev closeView filingShare - 5d agoOvernight26.10.20 10:404Ownership
IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals insider Shannon L. Devers reported changes in beneficial ownership of securities effective October 15, 2026. This filing serves as an official Form 4 statement regarding the insider's equity holdings.…more
$43.84+2.18%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16Pre-market26.10.16 19:48#●●●#●●●
Ionis Pharmaceuticals Receives Positive CHMP Opinion for TRYNGOLZA in EU…more
Ionis Pharmaceuticals' TRYNGOLZA has received a positive opinion from the EMA's CHMP for the treatment of adult patients with severe hypertriglyceridemia. If finalized by the European Commission, it would become the first RNA-targeted therapy authorized for this condition in the EU.…more
$43.84+2.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23Pre-market26.09.23 21:13
●●●●●●●● ●●●●● ●●●●●●
Ionis Pharmaceuticals and Roche announced that their investigational drug sefaxersen met its primary endpoint of significant proteinuria reduction in a Phase 3 trial for IgA nephropathy. The results suggest the therapy could offer a new way to slow disease progression and preserve long-term kidney function.…more
$43.84+2.18%vs prev closeShareBenzinga - 9.23Pre-market26.09.23 17:51
●●●●●●●● ●●●●● ●●●●●●
Ionis Pharmaceuticals and Roche announced that their Phase 3 study of Sefaxersen for IgA nephropathy met its primary endpoint of significant proteinuria reduction. The positive interim data will be shared with health authorities to support future regulatory submissions.…more
$43.84+2.18%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report